| Revenue growth | 10.6% YoY in Q3; 9.4% YoY in 9M FY26. |
|---|---|
| Margins | Gross margin expanded 184bps to 58.1% due to soft raw material costs. |
| Order book | U.S. order book at $220 million plus. |
| Demand visibility | Strong U.S. order book; seasonal uptick in cough/cold/pain segments. |
| Management confidence | High; optimistic on U.S. market and European expansion. |
Growth
Revenue grew 10.6% YoY to ₹754.4cr; EBITDA up 23.2% to ₹160.7cr; PAT up 8.2% to ₹113.7cr.
Outlook
Targeting ₹4,000cr revenue milestone by FY28/29; aggressive U.K. filings; active acquisition search in Europe.
Risks
Rx price erosion in U.K./U.S.; geopolitical uncertainties; macroeconomic challenges in Rest of World markets.
Earnings Call filed with NSE, NSE: MARKSANS. Summary written with AI assistance from the document.
Marksans Pharma Ltd: key numbers
- Share price
- ₹336.95
- Market cap
- ₹15,269 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 29.6×Sector 50.4×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 17.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Investor Presentation: Key Takeaways
Strong Q1FY27 performance driven by European growth and acquisitions. Marksans achieved highest-ever quarterly EBITDA and PAT, while crossing INR1,000 Cr cash balance.
- Call
- Guides 20% growth
Marksans Pharma Q1 FY27 Results: Net Profit ₹159.4 Cr, Up 173.9% YoY
Marksans Pharma Ltd reported revenue from operations of ₹840.8 Cr (+35.6% YoY) and net profit of ₹159.4 Cr (+173.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹159.4 Cr · +173.9% YoY
Marksans Pharma Earnings Call Transcript: Key Takeaways
Marksans Pharma delivered record FY26 results, crossing INR 3,000 Cr net income with 20.4% EBITDA margins. Management strategy focuses on diversification across US, UK, and Europe markets with high cash generation.
- Call
- Guides 20% growth
Marksans Pharma Earnings Call: Key Takeaways
Marksans Pharma delivered record FY26 performance, crossing ₹3,000cr net income with highest-ever profitability. Strategy focuses on geographic diversification (US, UK, Australia) and transitioning to branded prescription generics.